Abstract:AIM: To explore the association between AT-rich interactive domain 1A (ARID1A) protein loss by immunohistochemistry and both clinicopathologic characteristics and prognosis in patients with colorectal cancer.METHODS: We retrospectively collected clinicopathologic data and archived paraffin-embedded primary colorectal cancer samples from 209 patients, including 111 patients with colon cancer and 98 patients with rectal cancer. The tumor stage ranged from stage. to stage. according to the 7th edition of the American Joint Committee on Cancer tumor-node-metastasis (TNM) staging system. All patients underwent resection of primary colorectal tumors. The expression of ARID1A protein in primary colorectal cancer tissues was examined by immunohistochemical staining. The clinicopathologic association and survival relevance of ARID1A protein loss in colorectal cancer were analyzed.RESULTS: ARID1A loss by immunohistochemistry was not rare in primary colorectal cancer tumors (25.8%). There were 7.4%, 24.1%, 22.2% and 46.3% of patients with ARID1A loss staged at TNM stage I, II, III and IV, respectively, compared with 20.0%, 22.6%, 27.7% and 29.7% of patients without ARID1A loss staged at TNM stage I, II, III and IV, respectively. In patients with ARID1A loss, the distant metastasis rate was 46.3%. However, only 29.7% of patients without ARID1A loss were found to have distant metastasis. In terms of pathologic differentiation, there were 25.9%, 66.7% and 7.4% with poorly, moderately and well differentiated tumors in patients with ARID1A loss, and 14.2%, 72.3% and 13.5% with poorly, moderately and well differentiated tumors in patients without ARID1A loss, respectively. ARID1A loss was associated with late TNM stage (P = 0.020), distant metastasis (P = 0.026), and poor pathological classification (P = 0.035). However, patients with positive ARID1A had worse overall survival compared to those with negative ARID1A in stage. colorectal cancer (HR = 2.49, 95%CI: 1.13- 5.51).CONCLUSION: ARID1A protein loss is associated with clinicopathologic characteristics in colorectal cancer patients and with survival in stage. patients. (C) 2014 Baishideng Publishing Group Inc. All rights reserved.

Proteomic insights into the regulatory function of ARID1A in colon cancer cells

ARID1A overexpression inhibits colorectal cancer cell migration through the regulation of epithelial‑mesenchymal transition

ARID1A expression in early stage colorectal adenocarcinoma: an exploration of its prognostic significance

ARID1A is Downregulated in Non-Small Cell Lung Cancer and Regulates Cell Proliferation and Apoptosis

Pan-cancer Analysis of ARID1A Alterations As Biomarkers for Immunotherapy Outcomes

Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma

Chromatin Remodeling Gene AT-rich Interactive Domain-Containing Protein 1A Suppresses Gastric Cancer Cell Proliferation by Targeting PIK3CA and PDK1.

ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response

Clinicopathologic and Prognostic Relevance of ARID1A Protein Loss in Colorectal Cancer.

Decreased Expression of ARID1A Invasively Downregulates the Expression of Ribosomal Proteins in Hepatocellular Carcinoma

Expression of ARID1B is Associated with Poor Outcomes and Predicts the Benefit from Adjuvant Chemotherapy in Bladder Urothelial Carcinoma

Tumor suppressor role of chromatin-remodeling factor ARID1A]

ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.

Arid1a Mutation Promotes Cell Proliferation and Invasion, and Leads to Broad Drug Resistance in Colorectal Cancer

Arid1a Has Context-Dependent Oncogenic and Tumor Suppressor Functions in Liver Cancer

Research Progress of the Tumor Suppressor ARID1A

ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity

Prognostic role of ARID1A negative expression in gastric cancer

Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency

ARID1A Deficiency Weakens BRG1-RAD21 Interaction That Jeopardizes Chromatin Compactness and Drives Liver Cancer Cell Metastasis.

Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy